This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants (NCT02761187), a registered phase not stated study. The primary outcome is Number of Participants With Co-morbidities.
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT02761187 |
| Phase | Phase not stated |
| Condition | Multiple Myeloma |
| Allocation | Not Stated |
| Design model | Not Stated |
| Masking | Not Stated |
| Enrollment | 4253 |
| Arms in the primary outcome | n/a |
| Lead sponsor | Takeda |
| Results posted | Yes |
2. Clinical Question
Population
Participants with multiple myeloma, considered in newly diagnosed and relapsed/refractory groups. Newly diagnosed participants were enrolled within 3 months from treatment initiation; the relapsed/refractory group had received 1 to 3 prior lines of therapy.
Intervention
No intervention was assigned. The study observed treatment choices and clinical outcomes during routine care, rather than assigning a study treatment.
Comparator
There is no randomized control group. Treatment patterns and outcomes could be described across groups or strategies, but the registry record does not establish a like-for-like comparison between them.
Primary question
The primary outcome was the number of participants with comorbidities, represented using the Charlson Comorbidity Index. The broader study aimed to describe participant characteristics, disease presentation, treatment patterns, and clinical outcomes in newly diagnosed and relapsed/refractory multiple myeloma.
This is a descriptive observational question, not a randomized test of whether one treatment is better than another. The study was designed to record what treatments were chosen and what clinical outcomes were observed in practice. Those descriptions may help characterize care and identify patterns for further investigation, but treatment selection was not controlled by random assignment.
The record lists secondary outcomes concerning treatment combinations and sequencing, rechallenge, clinical outcomes across strategies, treatment at relapse, reasons for treatment modification, and healthcare resource use. These topics broaden the descriptive scope beyond the primary comorbidity measure. The record does not report results for those secondary outcomes in the registry record for this account.
The registry lists an enrollment of 4253, but the primary endpoint result and the number analyzed for that endpoint are not reported in the registry record. Thus, the central question can be described from the study plan, but the posted information does not establish the observed comorbidity distribution.
3. Trial Design
INSIGHT-MM is described in the registry as a global, prospective, non-interventional, observational study. Its purpose was to document real-world participant characteristics, clinical disease presentation, treatment regimens, and clinical outcomes in multiple myeloma. The registry lists Takeda as sponsor and an enrollment of 4253. The study status is TERMINATED.
Two participant groups are described. The newly diagnosed group included participants diagnosed with multiple myeloma within 3 months from treatment initiation. The relapsed/refractory group included participants who had received 1 to 3 prior lines of therapy. The descriptions state that participants were enrolled for 3 years and followed for at least 2 years, until death or the end of the study, whichever came first, up to approximately 5 years. These are the registry’s group descriptions; the record does not provide participant-level follow-up durations.
The study lists no intervention. This is consistent with its non-interventional design: treatment was observed as chosen in practice rather than assigned by the study. The record does not state how treatment decisions were made or whether particular treatment strategies were used at particular sites.
The listed start date is 2016-07-01, and the primary completion date is 2021-09-30. The reason for termination is not reported in the registry record. Nor does the record state whether termination changed the planned follow-up or affected the availability of particular outcomes.
The record lists 28 outcome measures and 0 analyses. It does not provide a statistical analysis plan, a sample-size justification, or detail about planned interim analyses. Therefore, design features beyond the stated observational structure and follow-up descriptions cannot be inferred from the registry entry.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Before assignment: Prospective data was collected for newly diagnosed multiple myeloma (NDMM) and Relapsed/Refractory multiple myeloma (RRMM) participants. Participants were also divided for analysis of some part of this study according to lines of therapy (LOT) they received. The final outcomes analysis performed at the end of study included 3263 participants excluding 990 participants from 4253 due to concerns around the robustness of data. Participants who received \>1 LOT were counted more than once.
Overall Study
| Stage | Newly Diagnosed (ND) MM | Relapsed/Refractory (R/R) MM |
|---|---|---|
| STARTED | 2338 | 1915 |
| 1st Line of Therapy | 2193 | 68 |
| 2nd Line of Therapy | 928 | 950 |
| 3rd Line of Therapy | 406 | 1049 |
| 4th Line of Therapy | 185 | 727 |
| >4th Line of Therapy | 153 | 767 |
| Line of Therapy: Unknown | 54 | 93 |
| COMPLETED | 0 | 0 |
| NOT COMPLETED | 2338 | 1915 |
Reasons for not completing this period:
| Reason | Newly Diagnosed (ND) MM | Relapsed/Refractory (R/R) MM |
|---|---|---|
| Too ill to Participate | 13 | 8 |
| Patient declined participation and declined follow-up for survival | 34 | 26 |
| Patient withdrew consent | 64 | 58 |
| Physician discretion | 4 | 8 |
| Change in physician or transferred to another treatment center | 72 | 62 |
| On Hospice | 20 | 26 |
| Deceased | 474 | 642 |
| Lost to Follow-up | 73 | 63 |
| Due to study discontinued at site | 100 | 85 |
| Reason not Specified | 1484 | 937 |
Analysis population for the primary outcome, as defined in the registry: All Enrolled Population included all participants who signed the inform consent form. Overall number of participants analyzed is the number of participants available for analysis.
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
Population: All Enrolled Population included all participants who signed the inform consent form.
| Characteristic | Unit | NDMM | RRMM | Total |
|---|---|---|---|---|
| Participants analysed | 2338 | 1915 | 4253 | |
| Age, Continuous | years | 64.7 (SD 10.94) | 66.0 (SD 10.42) | 65.2 (SD 10.72) |
| Sex: Female, Male: Female | Participants | 1317 | 1128 | 2445 |
| Sex: Female, Male: Male | Participants | 1021 | 787 | 1808 |
| Ethnicity (NIH/OMB): Hispanic or Latino | Participants | 348 | 285 | 633 |
| Ethnicity (NIH/OMB): Not Hispanic or Latino | Participants | 1297 | 1004 | 2301 |
| Ethnicity (NIH/OMB): Unknown or Not Reported | Participants | 693 | 626 | 1319 |
| Race (NIH/OMB): American Indian or Alaska Native | Participants | 0 | 0 | 0 |
| Race (NIH/OMB): Asian | Participants | 230 | 160 | 390 |
| Race (NIH/OMB): Native Hawaiian or Other Pacific Islander | Participants | 0 | 0 | 0 |
| Race (NIH/OMB): Black or African American | Participants | 153 | 111 | 264 |
| Race (NIH/OMB): White | Participants | 1506 | 1273 | 2779 |
| Race (NIH/OMB): More than one race | Participants | 25 | 16 | 41 |
| Race (NIH/OMB): Unknown or Not Reported | Participants | 424 | 355 | 779 |
6. Primary Endpoint
The registry lists the primary outcome as Number of Participants With Co-morbidities, measured over Baseline up to 5 years.
| Element | Registry entry |
|---|---|
| Result type | Count Of Participants |
| Measure of spread | not applicable |
| Unit | Participants |
| Endpoint classification | Binary Endpoint |
The primary outcome is titled “Number of Participants With Co-morbidities.” It is measured in participants over a timeframe described as baseline up to 5 years. The outcome description says that the Charlson Comorbidity Index (CCI) was used to represent comorbidities. The index assigns weights to comorbidity categories and sums those weights to produce a score for each participant.
The record describes a score of 0 as indicating no comorbidities found, and gives increasing severity descriptions for higher scores, with a score of 5 or higher described as moribund. It also states that higher scores correspond to a greater predicted likelihood of mortality or higher resource use. This makes the index a way to characterize overall comorbidity burden, rather than simply a count of each separate disease.
Comorbidity information can be useful in describing a clinical population because participants with the same cancer diagnosis may differ in other health conditions. In general, a comorbidity measure can help readers understand the health profile of the study population and provide context for observed treatment patterns and outcomes. It does not, by itself, show that comorbidities caused an outcome or that a treatment changed comorbidity burden.
The registry record does not report the observed CCI scores, the number of participants in each score category, or the analyzed count for this endpoint. The endpoint’s measure is described, but its numerical result is not reported in the registry record.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The information supports a description of study scope and selected posted counts, but not a treatment-effect conclusion. INSIGHT-MM was observational and non-interventional, with no randomized control group. Treatment choices therefore arose in clinical practice rather than through random assignment. Participants receiving different therapies or reaching different treatment lines may also differ in disease history, health status, prior treatment, or other characteristics. The registry record does not report adjustments that would account for such differences.
The primary outcome concerns comorbidities represented through the CCI. Although the registry describes how the index is scored, it does not report the observed endpoint result or the number analyzed. Consequently, the record does not show the comorbidity distribution in the enrolled population. It also does not provide estimates of uncertainty for that outcome.
The adverse-event information is presented by therapy line and includes counts labeled as at risk, affected, and deaths, as well as percentages for the most common serious terms. These are descriptive counts. The posted information does not provide a randomized comparison, adjusted estimates, or a basis for attributing an event to a particular treatment. Counts across therapy lines should not be treated as if they came from comparable groups without additional information about participant characteristics, exposure, observation time, and how the groups were formed.
The record lists 28 outcome measures but 0 analyses. The absence of listed analyses means the registry information does not specify which comparisons, models, or inferential procedures were used. A p-value, confidence interval, or adjusted treatment contrast is not reported in the record details. No conclusion about statistical significance or the size and precision of a treatment effect can therefore be drawn from these details.
In general, descriptive results can show what was recorded in the study, while causal conclusions require stronger support about comparability, measurement, and confounding. A large enrollment does not remove those design limitations. The registry’s enrollment is 4253, but enrollment alone cannot establish that estimates are unbiased or precise, particularly when the analyzed population and outcome-specific denominators are not reported. The most defensible interpretation is that the study was intended to characterize real-world patterns, while the registry information available for this account leaves many numerical outcome results and analytic details unreported.
9. Statistical Methods Explained
The registry describes an observational study, not a randomized experiment. In a randomized study, assignment by chance is used to make treatment groups comparable on average. In this study, treatment was not assigned. General statistical interpretation therefore needs to distinguish observed associations or group descriptions from causal effects. If participants receiving different regimens differ in their clinical history or health status, those differences can contribute to outcome patterns as well as treatment itself.
The primary outcome is a count of participants with comorbidities represented through the CCI. A count states how many participants meet a specified definition, but it is most interpretable alongside the denominator: the number of participants assessed for that outcome. The registry defines the enrolled population as participants who signed the informed consent form and says the overall analyzed number is the number available for analysis. It does not report the endpoint-specific number analyzed or the observed count. A rate, percentage, or uncertainty interval for the primary outcome therefore cannot be recovered from the record details.
In general, a confidence interval describes the range of values reasonably compatible with an estimate under the assumptions of the statistical method. It communicates precision as well as direction or magnitude. A count without an interval may be useful descriptively, but it does not show how much statistical uncertainty surrounds the result. No confidence interval for the primary outcome is reported in the registry record.
The CCI is a weighted summary, rather than a simple tally in which every comorbidity contributes equally. The registry explains that categories receive weights from 1 to 6 and that the weights are summed for each participant. In general, using a composite score can condense information into a single measure, but that summary does not show which specific conditions contributed to a participant’s score. The registry describes score interpretation but does not report the observed score distribution.
The adverse-event entries use therapy-line groups and distinguish serious events from other events in the posted count fields. Such counts are descriptive and depend on the definitions used to identify an event and the period over which participants were observed. In general, counts alone do not account for different lengths of observation. A comparison of event frequency across groups would need appropriate denominators and a clearly specified time basis; the record details do not report a method for estimating comparative event rates or adjusting for exposure time.
The listed planning assumptions describe an illustration based on an observed effect, a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. The illustration considers fractions of the observed effect. These assumptions describe a planning calculation, not the study’s own design or an observed power analysis. Because the study is non-interventional and does not have a randomized allocation to two arms, the illustration should not be read as evidence that the study was designed or powered for a controlled treatment comparison. No sample-size justification is reported in the registry record.
In general, a planning sample size asks how many participants might be needed under specified assumptions to detect a chosen effect with a chosen level of statistical power. It does not measure the probability that a particular result is true, and it is not the same as observed power calculated after a study. Any planning illustration based on an observed effect also depends on that effect being a useful planning assumption. The registry record does not report the basis for selecting the observed effect or the fractions considered beyond the stated planning description.
The record lists 0 analyses. It does not name a regression model, a method for handling repeated observations, an approach to time-to-event outcomes, or a procedure for adjusting for confounding. Those details are not reported in the registry record and should not be inferred from the outcome titles alone. In general, the choice of model should match the outcome type, study design, follow-up structure, and estimand. Different reasonable methods can yield different estimates, particularly when data are incomplete or participant follow-up varies.
Multiplicity refers to the statistical challenge created when many outcomes or comparisons are examined. In general, considering more hypotheses can increase the chance of at least one apparently unusual result by chance, unless the analysis plan addresses that issue. The registry lists 28 outcome measures, but no multiplicity procedure is reported. It is not possible to determine from the record whether outcomes were prioritized in a detailed analysis plan or how any multiple testing was handled.
10. Multiplicity, Missing Data and Analysis Populations
The registry lists 28 outcome measures and 0 analyses. This indicates that the record contains outcome descriptions without a corresponding list of statistical analyses in the information. The registry record does not report whether a multiplicity strategy was planned or used. In general, when many outcomes or comparisons are considered, the chance of finding at least one apparently notable result by chance can rise. A prespecified hierarchy, adjustment procedure, or clearly identified exploratory analysis can help readers interpret a collection of results, but none is described in the record details.
Missing-data information is also limited. The primary outcome’s population description says that the overall number analyzed is the number of participants available for analysis. However, the record does not report the number available for the primary endpoint, the amount or pattern of missing data, reasons for missingness, or the method used to handle missing observations. It is therefore not possible to assess whether participants with observed data differed from those without data, or how missingness might affect the results.
The group descriptions specify enrollment and follow-up plans, including follow-up until death or the end of the study, whichever came first. They do not provide participant-level follow-up, loss-to-follow-up counts, or an explanation of how outcomes were handled when follow-up ended. The registry status is TERMINATED, but the reason for termination and any effect on outcome completeness are not reported in the registry record.
The record does not state whether analyses used an all-enrolled population, an outcome-specific available-case population, or another analysis population beyond the general description of participants available for analysis. Those details matter because different analysis populations can produce different descriptive estimates. No assumptions about missingness or sensitivity analyses should be inferred.
11. Safety Results
The registry reports serious adverse events as affected participants divided by participants at risk.
| Arm | Participants with serious adverse events | Participants at risk | Percentage |
|---|---|---|---|
| 1st Line of Therapy | 269 | 1849 | 14.5% |
| 2nd Line of Therapy | 101 | 773 | 13.1% |
| 3rd Line of Therapy | 82 | 455 | 18.0% |
| 4th Line of Therapy | 43 | 239 | 18.0% |
| >4th Line of Therapy | 38 | 181 | 21.0% |
Deaths
| Arm | Deaths (participants affected of at risk) |
|---|---|
| 1st Line of Therapy | 351 of 1790 |
| 2nd Line of Therapy | 418 of 1331 |
| 3rd Line of Therapy | 420 of 1050 |
| 4th Line of Therapy | 348 of 739 |
| >4th Line of Therapy | 234 of 453 |
| Robustness Concerns: 1st Line of Therapy | 58 of 340 |
Other (non-serious) adverse events
Participants with at least one non-serious event at or above the registry's 0% reporting threshold.
| Arm | Participants affected of at risk |
|---|---|
| 1st Line of Therapy | 306 of 1849 |
| 2nd Line of Therapy | 125 of 773 |
| 3rd Line of Therapy | 79 of 455 |
| 4th Line of Therapy | 39 of 239 |
| >4th Line of Therapy | 32 of 181 |
| Robustness Concerns: 1st Line of Therapy | 0 of 0 |
Most frequent serious adverse event terms
| Event term | Organ system | 1st Line of Therapy | 2nd Line of Therapy | 3rd Line of Therapy | 4th Line of Therapy | >4th Line of Therapy | Robustness Concerns: 1st Line of Therapy |
|---|---|---|---|---|---|---|---|
| Pneumonia | Infections and infestations | 42 of 1849 | 17 of 773 | 17 of 455 | 5 of 239 | 3 of 181 | 0 of 0 |
| Acute kidney injury | Renal and urinary disorders | 10 of 1849 | 3 of 773 | 4 of 455 | 4 of 239 | 2 of 181 | 0 of 0 |
| Pyrexia | General disorders | 10 of 1849 | 3 of 773 | 4 of 455 | 2 of 239 | 2 of 181 | 0 of 0 |
| Sepsis | Infections and infestations | 8 of 1849 | 4 of 773 | 3 of 455 | 1 of 239 | 2 of 181 | 0 of 0 |
| Thrombocytopenia | Blood and lymphatic system disorders | 2 of 1849 | 2 of 773 | 4 of 455 | 4 of 239 | 4 of 181 | 0 of 0 |
| Plasma cell myeloma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 5 of 1849 | 2 of 773 | 4 of 455 | 1 of 239 | 3 of 181 | 0 of 0 |
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | 5 of 1849 | 4 of 773 | 1 of 455 | 1 of 239 | 3 of 181 | 0 of 0 |
| Anaemia | Blood and lymphatic system disorders | 6 of 1849 | 1 of 773 | 1 of 455 | 2 of 239 | 3 of 181 | 0 of 0 |
| Atrial fibrillation | Cardiac disorders | 7 of 1849 | 1 of 773 | 1 of 455 | 0 of 239 | 4 of 181 | 0 of 0 |
| Cardiac failure congestive | Cardiac disorders | 9 of 1849 | 2 of 773 | 0 of 455 | 1 of 239 | 1 of 181 | 0 of 0 |
Most frequent non-serious adverse event terms
| Event term | Organ system | 1st Line of Therapy | 2nd Line of Therapy | 3rd Line of Therapy | 4th Line of Therapy | >4th Line of Therapy | Robustness Concerns: 1st Line of Therapy |
|---|---|---|---|---|---|---|---|
| Neuropathy peripheral | Nervous system disorders | 64 of 1849 | 31 of 773 | 15 of 455 | 6 of 239 | 7 of 181 | 0 of 0 |
| Peripheral sensory neuropathy | Nervous system disorders | 43 of 1849 | 9 of 773 | 3 of 455 | 3 of 239 | 2 of 181 | 0 of 0 |
| Diarrhoea | Gastrointestinal disorders | 24 of 1849 | 14 of 773 | 13 of 455 | 5 of 239 | 1 of 181 | 0 of 0 |
| Thrombocytopenia | Blood and lymphatic system disorders | 12 of 1849 | 14 of 773 | 14 of 455 | 4 of 239 | 8 of 181 | 0 of 0 |
| Fatigue | General disorders | 25 of 1849 | 10 of 773 | 8 of 455 | 5 of 239 | 1 of 181 | 0 of 0 |
| Neutropenia | Blood and lymphatic system disorders | 16 of 1849 | 3 of 773 | 3 of 455 | 3 of 239 | 3 of 181 | 0 of 0 |
| Constipation | Gastrointestinal disorders | 13 of 1849 | 7 of 773 | 1 of 455 | 1 of 239 | 0 of 181 | 0 of 0 |
| Oedema peripheral | General disorders | 11 of 1849 | 4 of 773 | 4 of 455 | 0 of 239 | 1 of 181 | 0 of 0 |
| Anaemia | Blood and lymphatic system disorders | 4 of 1849 | 2 of 773 | 5 of 455 | 2 of 239 | 3 of 181 | 0 of 0 |
| Nausea | Gastrointestinal disorders | 4 of 1849 | 3 of 773 | 7 of 455 | 0 of 239 | 1 of 181 | 0 of 0 |
Serious events with the highest arm-level rate: pneumonia (3.7%), thrombocytopenia (2.2%), atrial fibrillation (2.2%), lower respiratory tract infection (1.8%), acute kidney injury (1.7%).
The adverse-event entries are organized by therapy line. For the first line of therapy, the record lists 1849 at risk for serious events and 269 affected; it separately lists 1849 at risk for other events and 306 affected. The record also displays a deaths count of 351 for that row. These are posted counts, not comparative treatment-effect estimates. The entries for later therapy lines have different at-risk counts, so raw counts across lines are not directly comparable.
The most common serious terms listed are pneumonia at 3.7%, thrombocytopenia at 2.2%, atrial fibrillation at 2.2%, lower respiratory tract infection at 1.8%, acute kidney injury at 1.7%, and anaemia at 1.7%. These percentages describe the posted term frequencies; the record details do not supply further detail on the event definitions, exposure time, or whether events were judged related to treatment. They should not be interpreted as risks caused by a particular regimen.
The record also includes rows labeled as robustness concerns, with zero at risk and zero affected, alongside deaths counts. The registry information does not explain those rows, so the zero event counts should not be interpreted as evidence that no events occurred in the corresponding therapy-line populations. The displayed deaths counts are not sufficiently defined in the record details to establish their relationship to adverse events or treatment.
12. What the Result Does, and Does Not, Mean
The study’s intended contribution is descriptive: to document multiple myeloma presentation, treatment patterns, and outcomes in routine care, including newly diagnosed and relapsed/refractory disease. The primary outcome adds a comorbidity measure through the CCI. These questions are relevant to understanding the characteristics of the population being observed and how care is delivered across treatment histories.
The posted registry information does not establish that one treatment is more effective or safer than another. No treatment was assigned by the study, and the registry explicitly does not provide a like-for-like control comparison. Differences in treatment groups may reflect differences in participants or clinical circumstances. Counts and percentages can describe what was recorded, but they cannot by themselves separate treatment effects from those other factors.
The primary comorbidity outcome is described, but its numerical result is not reported in the registry record. The record also does not list statistical analyses. Thus, there is no reported primary estimate, uncertainty interval, or inferential result to interpret from these registry entries. The adverse-event counts and term percentages provide descriptive information, but without detailed definitions, exposure-time information, or adjusted comparisons they do not support causal conclusions.
In general, observational findings can identify patterns and generate questions for more focused analysis. Their interpretation depends on the completeness of measurement, the population included in each analysis, and the methods used to address confounding and missing data. Those analytic details are not reported in the registry record. The enrollment of 4253 describes the listed study enrollment, not the number necessarily contributing data to every endpoint.
The appropriate reading is therefore bounded: the registry sets out a broad real-world descriptive study and reports selected safety counts, but the available record does not provide enough outcome results or methodological detail to determine the precision, completeness, or causal meaning of treatment-related patterns.
13. Why This Trial Matters Statistically
Statistically, INSIGHT-MM illustrates the difference between documenting clinical practice and testing a treatment contrast. A prospective observational study can collect information about presentation, treatment choices, and outcomes as they occur in practice. That broad view can describe patterns across newly diagnosed and relapsed/refractory multiple myeloma, including treatment sequencing and resource use, without imposing a study treatment.
The same design makes interpretation of differences more challenging. Since treatment is not randomly assigned, participant characteristics and clinical decisions may be linked to both treatment choice and outcome. General statistical methods can attempt to adjust for measured differences, but the registry record does not report analyses or adjustment methods. Unmeasured differences may remain even when measured characteristics are considered.
The CCI endpoint also demonstrates why a clearly named measure matters. The outcome is described as a number of participants with comorbidities, while the method represents comorbidity through a weighted score. These are related but not identical forms of information: a weighted score summarizes categories, and its distribution can provide context about overall comorbidity burden. The record explains the measure but does not report its observed distribution.
Finally, a large listed enrollment does not substitute for reporting endpoint-specific denominators, missingness, analytic methods, and uncertainty. Those details determine what a reader can conclude from observed data. The registry’s 28 outcome measures and 0 listed analyses make the distinction especially important: the study’s broad descriptive aims are clear, while the methods and numerical results needed to evaluate many of those aims are not reported in the registry record.
14. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
The registry record provides limited outcome results and analytic detail. It lists the primary comorbidity outcome but does not report its observed count, CCI distribution, endpoint-specific analyzed population, or uncertainty. It also lists 28 outcomes and 0 analyses, so the record does not identify the statistical procedures used or the comparisons made.
The non-interventional design means treatment was not randomly assigned. As a result, treatment groups should not be treated as interchangeable, and observed differences may reflect participant characteristics or clinical decisions as well as treatment. The record does not report adjustment methods or enough detail to assess the extent to which potential confounding was addressed.
Follow-up is described as lasting at least 2 years and up to approximately 5 years, ending at death or the study end, whichever came first. Actual follow-up distributions, outcome-specific observation periods, and losses to follow-up are not reported in the registry record. The status is TERMINATED, but the reason and its implications for completeness are not reported.
The adverse-event information includes counts by therapy line and percentages for serious terms, but the record details do not specify event ascertainment details, exposure time, or the basis for the deaths counts. The rows labeled as robustness concerns are also not explained. These limitations prevent straightforward comparison of counts across groups and limit causal interpretation.
The enrollment of 4253 should not be assumed to be the denominator for every outcome. The registry defines the analyzed number as participants available for analysis, but does not give endpoint-specific numbers or missing-data methods. Sample-size illustrations are planning calculations based on stated assumptions, not the study’s own design justification or observed power.
15. Related Tutorials
16. Related Statistical Calculators
17. Sources
- ClinicalTrials.gov: An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants — NCT02761187.
- Registry record last updated 2025-02-24; status last verified 2025-01.
- Results first posted 2025-02-24.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
18. Record Summary
NCT02761187, titled An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants, is listed as a global, prospective, non-interventional observational study sponsored by Takeda. The registry reports an enrollment of 4253 and a status of TERMINATED. The listed start date is 2016-07-01, and the primary completion date is 2021-09-30.
The study describes newly diagnosed participants enrolled within 3 months from treatment initiation and relapsed/refractory participants with 1 to 3 prior lines of therapy. Its primary outcome is the number of participants with comorbidities, represented using the Charlson Comorbidity Index. The registry lists 28 outcome measures and 0 analyses.
The record includes adverse-event counts by therapy line and percentages for selected serious terms. The reason for termination, primary endpoint result, endpoint-specific analyzed population, missing-data methods, statistical analysis plan, and multiplicity approach are not reported in the registry record.